TABLE 3.
Statistical analysis of plasma viral RNA load measured in different vaccine groups after SHIVKU2 challenge
| Group comparisona |
P
|
|
|---|---|---|
| AUC | Peak viremia | |
| vCP250/gp120 (group A) vs naive (group E) | 0.049 | 0.026 |
| vCP1420/gp160 (groups B and C) vs naive (group E) | 0.072 | 0.089 |
| vCP172 (group D) vs naive (group E) | 0.73 | 0.73 |
| vCP250/gp120 (group A) and vCP1420/gp160 (groups B and C) vs naive (group E) | 0.027 | 0.025 |
| vCP250/gp120 (group A) vs vCP172 (group D) and naive (group E) | 0.041 | 0.013 |
| vCP1420/gp160 (groups B and C) vs vCP172 (group D) and naive (group E) | 0.062 | 0.099 |
| vCP250/gp120 (group A) and vCP1420/gp160 (groups B and C) vs vCP172 (group D) and naive (group E) | 0.019 | 0.019 |
| vCP250/gp120 (group A) vs vCP1420/gp160 (groups B and C) | 0.29 | 0.26 |
a
vCP250, ALVAC-HIV-1IIIB-gpe (gp120 Env); vCP1420, ALVAC-HIV-1IIIB-gpe (gp160 Env); vCP172, ALVAC-SIVmac251-gp.